Go Big 「Pharma」, or Go Home?

Dr. Angell
GSK, Arrow Therapeutics

img_5909

The UCLU Pharmaceutical Society’s second event was held again, at the School of Pharmacy, on Tuesday 17 November. Dr Richard Angell delivered a talk on his experience and how the sector of drug discovery progresses.

Dr Richard Angell, having worked for GlaxoSmithKline and Arrow Therapeutics Ltd, was an experienced scientist in drug discovery. He joined the Translational Research Office in 2012, to set up the Drug Discovery Centre at the UCL School of Pharmacy

GlaxoSmithKline is a world-leading pharmaceutical industry that focuses on research, development and manufacture of innovative pharmaceutical medicines, vaccines and consumer healthcare products. Conversely, Arrow Therapeutics is a London-based pharmaceutical company, focusing exclusively on the research and development of novel antiviral drugs. Dr Angell pointed out the advantages and disadvantages of big pharmaceutical companies, small biotechnology companies and universities in terms of size and structure; then speaking on how these factors can have an effect on their stability, management, finance and the atmosphere in general. His insightful view provided the freshers with a glance to the pharmaceutics industry and also the senior students a clear vision towards their future.

Leave a Reply